Butylated hydroxyanisole: Carcinogenic Potency Database

Butylated hydroxyanisole (CAS 25013-16-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
sto	sto	sto	no positive	405^m,P,v	5530^m,n

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
no positive	no test	no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: sto = stomach. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. n = No positive results in this species in the CPDB are statistically significant (p<.1). P = 100% of dosed animals had tumors at a target site in an experiment in this species. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD₅₀ values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Butylated hydroxyanisole: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



BUTYLATED HYDROXYANISOLE  (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5
922  H m syg eat 48w72 1997m                         0    1.23gm                                         Hirose;carc,11,239-244;1990
 for sqc r      5.44gm   P<.4       884.mg n.s.s.   0/9     1/14
 for pam r      no dre   P=1.       1.70gm n.s.s.   0/9     0/14
923  H m syg eat 72w72 1997n                         0    1.84gm
 for pam r      745.mg   P<.004     270.mg 4.82gm   0/9     5/9
 for sqc r      no dre   P=1.       1.64gm n.s.s.   0/9     0/9
924  M m b6c eat 64w64 1901m                         0    600.mg  1.20gm                     Masui;gann,77,1083-1090;1986/pers.comm.
 for tum ekr    no dre   P=1.       312.mg n.s.s.   0/10    0/10    0/10
925  M m b6c eat 72w72 1901n                         0    600.mg  1.20gm
 for tum ekr    no dre   P=1.       395.mg n.s.s.   0/10    0/10    0/10
926  M m b6c eat 80w80 1901o                         0    600.mg  1.20gm
 for pam ekr    1.02gm * P<.03      413.mg n.s.s.   0/10    3/10    3/10
927  M m b6c eat 88w88 1901r                         0    600.mg  1.20gm
 for pam ekr    3.75gm * P<.3       920.mg n.s.s.   0/10    1/7     1/10
 for sqc ekrh   3.75gm * P<.3    +  920.mg n.s.s.   0/10    1/7     1/10
928  M m b6c eat 96w96 1901s                         0    600.mg  1.20gm
 for pam ekr    1.53gm * P<.02      620.mg n.s.s.   0/13    3/9     3/11
 for sqc ekrh   10.5gm * P<.3    +  1.71gm n.s.s.   0/13    0/9     1/11
929  M m b6c eat 24m24 1901u                         0    600.mg  1.20gm
 for pam er     13.1gm * P<.4       3.21gm n.s.s.   0/16    1/21    1/22
 for sqc er     no dre   P=1.       1.76gm n.s.s.   0/16    0/21    0/22
930  M f lca eat 52w52 2402                          0    325.mg                                            Gao;scch,37,419-428;1994
 tba tum        no dre   P=1.    -  1.00gm n.s.s.   0/60    0/60
931  M b swi eat 24m24 1525                          0    625.mg                                             Maru;clet,17,75-80;1982
 lun tum r      5.11gm   P<.2       1.30gm n.s.s.   1/47    3/30
 liv tum r      no dre   P=1.       2.39gm n.s.s.   7/47    2/30
932  R f f34 eat 24m26 1568                          0    232.mg  929.mg                                    Ito;jnci,70,343-352;1983
 for pam e      490.mg / P<.0005 +  334.mg 744.mg   0/51    1/51   49/51
 for sqc e      2.75gm / P<.0005 +  1.51gm 5.82gm   0/51    0/51   15/51
 liv hnd e      162.gm * P<.9       8.36gm n.s.s.   1/51    0/51    1/51
933  R m f34 eat 24m26 1568                          0    186.mg  743.mg
 for pam e      349.mg / P<.0005 +  238.mg 528.mg   0/51    1/50   52/52
 for sqc e      1.80gm / P<.0005 +  1.04gm 3.56gm   0/51    0/50   18/52
 liv hnd e      no dre   P=1.       4.38gm n.s.s.   4/51    3/50    3/52
934  R m f34 eat 60w60 1640                          0    200.mg                                          Rao;canr,44,1072-1076;1984
 liv tum er     no dre   P=1.       343.mg n.s.s.   0/25    0/25
935  R m f34 eat  6m24 1902m                         0    200.mg                                           Nera;txcy,53,251-268;1988
 for car e      no dre   P=1.       2.06gm n.s.s.   0/50    0/50
 for pam e      no dre   P=1.       2.06gm n.s.s.   0/50    0/50
 liv tum e      no dre   P=1.       2.06gm n.s.s.   0/50    0/50
936  R m f34 eat 12m24 1902n                         0    400.mg
 fls pam e      4.06gm   P<.04      1.23gm n.s.s.   0/50    3/46
 for sqc e      4.06gm   P<.04   +  1.23gm n.s.s.   0/50    3/46
 fgr pam e      12.5gm   P<.3       2.03gm n.s.s.   0/50    1/46
 liv tum e      no dre   P=1.       3.79gm n.s.s.   0/50    0/46
937  R m f34 eat 24m24 1902o                         0    800.mg
 fgr pam e      298.mg   P<.0005    186.mg 495.mg   0/50   37/44
 fls pam e      298.mg   P<.0005    186.mg 495.mg   0/50   37/44
 for sqc e      7.76gm   P<.04   +  2.35gm n.s.s.   0/50    3/44
 liv tum e      no dre   P=1.       7.25gm n.s.s.   0/50    0/44
938  R m f34 eat 26m26 1973                          0    480.mg                                       Williams;fctx,28,799-806;1990
 ssq sqp eh     907.mg   P<.0005 +  424.mg 2.67gm   0/25    9/27
 liv hpa e      no dre   P=1.       1.14gm n.s.s.   9/25    6/27
939  R m f3d eat 24m24 1784                          0    50.0mg  100.mg  200.mg  400.mg  800.mg          Ito;jnci,77,1261-1265;1986
 for pam e      598.mg Z P<.0005 +  431.mg 858.mg   0/50    0/50    0/50    0/50   10/50   50/50
 for sqc e      4.55gm Z P<.0005 +  2.28gm 11.1gm   0/50    0/50    0/50    0/50    0/50   11/50
 liv hpc e      no dre   P=1.       6.03gm n.s.s.   0/50    0/50    0/50    3/50    0/50    0/50
940  R m f3d eat 52w52 1883                          0    400.mg  800.mg                    Hasegawa;gann,79,320-328;1988/pers.comm.
 for mix        1.30gm * P<.08      393.mg n.s.s.   0/10    0/20    3/20
 for pam        1.99gm * P<.2    -  488.mg n.s.s.   0/10    0/20    2/20
 for sqc        4.04gm * P<.4    -  658.mg n.s.s.   0/10    0/20    1/20
 liv tum        no dre   P=1.    -  275.mg n.s.s.   0/10    0/20    0/20
941  R m f3d eat 52w52 1900                          0    400.mg  800.mg                     Hirose;carc,8,1731-1735;1987/pers.comm.
 eso tum er     no dre   P=1.    -  206.mg n.s.s.   0/10    0/15    0/15
 for tum er     no dre   P=1.    -  206.mg n.s.s.   0/10    0/15    0/15
 liv tum er     no dre   P=1.    -  206.mg n.s.s.   0/10    0/15    0/15
942  R m f3d eat 51w52 1921                          0    392.mg                                       Hirose;carc,10,2223-2226;1989
 for mix er     907.mg   P<.3    -  148.mg n.s.s.   0/10    1/14
 for pam er     907.mg   P<.3    -  148.mg n.s.s.   0/10    1/14
 for sqc er     907.mg   P<.3    -  148.mg n.s.s.   0/10    1/14
 stg tum er     no dre   P=1.    -  283.mg n.s.s.   0/10    0/14
943  R m f3d eat 52w52 2098                          0    800.mg                                        Shibata;carc,14,275-280;1993
 for sqp er     442.mg   P<.04      152.mg n.s.s.   0/10    4/15
 for sqc er     no dre   P=1.       618.mg n.s.s.   0/10    0/15
944  R m f3d eat 60w60 2134                          0    800.mg                                    Ito;anti,183-194;1990/pers.comm.
 for sqp er     1.06gm   P<.04      321.mg n.s.s.   0/19    3/19
 for sqc er     no dre   P=1.       1.04gm n.s.s.   0/19    0/19
945  R m f3d eat 51w51 2162 ()                       0    800.mg                                           Kawabe;gann,85,17-25;1994
 for sqc er     591.mg   P<.04   +  178.mg n.s.s.   0/15    3/15
 for sqp er     591.mg   P<.04      178.mg n.s.s.   0/15    3/15
 stg tum Cer    no dre   P=1.       595.mg n.s.s.   0/15    0/15
946  R m f3d eat 52w52 2192m                         0    400.mg                           Shibata;carc,14,1265-1269;1993/pers.comm.
 for tum er     no dre   P=1.       412.mg n.s.s.   0/10    0/20
947  R m f3d eat 24m24 2192n                         0    800.mg
 for sqp er     289.mg   P<.0005 +  144.mg 625.mg   0/17   17/20
 for sqc er     2.46gm   P<.03   +  846.mg n.s.s.   0/17    4/20
948  R m f3d eat 24m24 2568m                         0    800.mg                                         Tamano;fctx,36,299-304;1998
 for mix e      noTD50   P<.0005 +  n.s.s. 247.mg   1/30   30/30
 for sqp e      noTD50   P<.0005    n.s.s. 247.mg   1/30   30/30
 for sqc e      1.77gm   P<.0005 +  797.mg 5.79gm   0/30    8/30
 for lei e      16.2gm   P<.3       2.63gm n.s.s.   0/30    1/30
949  R m lwj eat 24m24 2568r                         0    800.mg
 for mix e      noTD50   P<.0005 +  n.s.s. 243.mg   0/30   30/30
 for sqp e      noTD50   P<.0005    n.s.s. 243.mg   0/30   30/30
 for sqc e      7.95gm   P<.1    +  1.95gm n.s.s.   0/30    2/30
950  R m sdj eat 24m24 2568o                         0    800.mg
 for mix e      noTD50   P<.0005 +  n.s.s. 243.mg   0/30   30/30
 for sqp e      noTD50   P<.0005    n.s.s. 243.mg   0/30   30/30
 for sqc e      1.20gm   P<.0005 +  598.mg 2.97gm   0/30   11/30
 for lei e      7.95gm   P<.1       1.95gm n.s.s.   0/30    2/30
951  R m shj eat 24m24 2568n                         0    800.mg
 for mix e      noTD50   P<.0005 +  n.s.s. 243.mg   0/30   30/30
 for sqp e      noTD50   P<.0005    n.s.s. 243.mg   0/30   30/30
 for sqc e      377.mg   P<.0005 +  217.mg 707.mg   0/30   23/30
 for lei e      16.2gm   P<.3       2.63gm n.s.s.   0/30    1/30

Mutagenicity in Salmonella: negative
SMILES Code for Butylated hydroxyanisole: OC1=CC=C(C=C1C(C)(C)C)OC
InChI Code for Butylated hydroxyanisole: InChI=1/C11H16O2/c1-11(2,3)9-7-8(13-4)5-6-10(9)12/h5-7,12H,1-4H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Butylated hydroxyanisole:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007